Be the first to review this item
Lucetam (Piracetamum, Piracetam) - neuroprotective drugs.
Piracetam - cyclic derivative of GABA. Direct impact on the brain. Lucetam improves cognitive (cognitive) processes, such as learning ability, memory, attention, ability to memorize, as well as improves mental performance, without the development of sedative and psychostimulant effect.
Has impact on the central nervous system in various ways: change the speed of propagation of excitation in the brain, improves neuronal plasticity and metabolic processes in the nerve cells. It improves the interaction between the hemispheres of the brain and synaptic conductance in neocortical structures, it improves mental performance, improves cerebral blood flow.
Lucetam improves microcirculation in the brain, affecting the rheological properties of blood and causes vasodilatory action. Lucetam inhibits platelet aggregation and restores the elasticity of erythrocyte membranes, as well as the ability of the latter to the passage through the microcirculation. It reduces adhesion of red blood cells. At a dose of 9.6 g reduces levels of fibrinogen and von Willebrand factor by 30-40% and prolongs bleeding time.
Lucetam has a protective and restorative action in violation of brain function due to hypoxia, intoxication or injury. It reduces the severity and duration of vestibular nystagmus.
Pregnancy and breast-feeding:
Animal studies have not revealed the damaging effect on the embryo and the development of the offspring, including in the postnatal period, and did not change during pregnancy and childbirth. Studies have not been conducted in pregnant women. Piracetam crosses the placental barrier and into breast milk. The concentration of the drug in infants up to 70-90% of its concentration in the blood of the mother. Except in special circumstances Lutsetam should not be administered during pregnancy. It should refrain from breast-feeding in the appointment of a woman Lutsetam.
In connection with the effect of piracetam on platelet aggregation caution should be prescribed to patients with impaired hemostasis during major surgery or in patients with symptoms of severe bleeding.
In the treatment of cortical myoclonus abrupt interruption of treatment should be avoided, which might cause the resumption of seizures.
It penetrates through the filtration membranes for hemodialysis machines.
When long-term therapy of elderly patients are advised to regularly monitor indicators of kidney function, if necessary, shall adjust the dose depending on the results of research spacecraft.
Taking into account possible side effects, the patient should be careful when driving and operating machinery.
Inside the drug is administered in a daily dose of 30-160 mg / kg, the multiplicity of reception - 2-4 times / day.
Lutsetam tablets taken with meals or on an empty stomach, with some liquid (water, juice).
administered 1.2-2.4 g / day, and during the first week in the symptomatic treatment of chronic psycho-organic syndrome depending on the severity of symptoms - 4.8 g / day.
In the treatment of the effects of stroke appoint 4.8 g / day.
When alcohol withdrawal syndrome - 12 g / day. The maintenance dose - 2.4 g / day.
For the treatment of vertigo and associated disorders of balance administered 2.4-4.8 g / day.
When cortical myoclonus treatment starts with a dose of 7.2 g / day, once every 3-4 days, increase the dose of 4.8 g / day to a maximum dose of 24 g / day. Treatment continued throughout the period of the disease. Every 6 months should attempt to reduce the dose or stop the drug, gradually reducing the dose of 1.2 g every 2 days in order to prevent an attack. In the absence of treatment effect or a slight therapeutic effect is stopped.
Babies for the correction of learning disabilities prescribed oral dose of 3.2 g / day. Treatment continues throughout the school year.
In patients with impaired function of the liver correction mode is not required.
In patients with impaired renal function requires correction dosing regimen according to creatinine clearance (CC). The degree of renal failure QC (ml / min) Dose Rate of> 80 Usual dose Light 50-79 2/3 usual dose is 2 - 3 admission average 30-49 1/3 usual dose in 2 hours Weight <30 1/6 usual dose, End-stage single - contraindicated
In elderly patients a dose of correcting the presence of renal insufficiency and long-term treatment is necessary to monitor renal function.
Important notice- the outer box design may vary before prior notice!
Someone from the Norway - just purchased the goods:
Kristagen 20 capsules